MOXIFLOXACIN-BAXTER moxifloxacin (as hydrochloride) 400 mg/250 mL solution for intravenous infusion bottle Australia - English - Department of Health (Therapeutic Goods Administration)

moxifloxacin-baxter moxifloxacin (as hydrochloride) 400 mg/250 ml solution for intravenous infusion bottle

baxter healthcare pty ltd - moxifloxacin hydrochloride, quantity: 1.74 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - moxifloxacin-baxter is indicated for treatment of adults who require initial i.v. therapy for the treatment of infections in the conditions: ? community acquired pneumonia (caused by susceptible organisms) ? acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics moxifloxacin-baxter is indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin-baxter may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

BAXTER POTASSIUM CHLORIDE 10 mmol and 0.29% SODIUM CHLORIDE 100 mL intravenous infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 10 mmol and 0.29% sodium chloride 100 ml intravenous infusion bag

baxter healthcare pty ltd - sodium chloride, quantity: 2.92 g/l; potassium chloride, quantity: 7.46 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

VALPROATE-AFT sodium valproate 300 mg/3 ml solution for intravenous infusion or injection vials Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 300 mg/3 ml solution for intravenous infusion or injection vials

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

VALPROATE-AFT sodium valproate 400 mg/4 ml solution for intravenous infusion or injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 400 mg/4 ml solution for intravenous infusion or injection ampoules

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

VALPROATE-AFT sodium valproate 1000 mg/10 ml solution for intravenous infusion or injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 1000 mg/10 ml solution for intravenous infusion or injection ampoules

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; nitrogen; water for injections; monobasic potassium phosphate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

VALPROATE-AFT sodium valproate 400 mg/4 ml solution for intravenous infusion or injection vials Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 400 mg/4 ml solution for intravenous infusion or injection vials

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

VALPROATE-AFT sodium valproate 300 mg/3 ml solution for intravenous infusion or injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 300 mg/3 ml solution for intravenous infusion or injection ampoules

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: nitrogen; dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

VALPROATE-AFT sodium valproate 1000 mg/10 ml solution for intravenous infusion or injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 1000 mg/10 ml solution for intravenous infusion or injection vial

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; nitrogen; monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

NIMODIPINE JUNO nimodipine 10 mg/50 mL concentrated intravenous infusion solution vial Australia - English - Department of Health (Therapeutic Goods Administration)

nimodipine juno nimodipine 10 mg/50 ml concentrated intravenous infusion solution vial

juno pharmaceuticals pty ltd - nimodipine, quantity: 10 mg - injection, intravenous infusion - excipient ingredients: citric acid; sodium citrate dihydrate; water for injections; ethanol; macrogol 400 - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm after subarachnoid haemorrhage following ruptured intracranial aneurysm, in patients who are in good neurological condition post-ictus, e.g., hunt and hess grades i-iii (see section 5.1 pharmacodynamic properties).

TRINTELLIX- vortioxetine tablet, film coated United States - English - NLM (National Library of Medicine)

trintellix- vortioxetine tablet, film coated

takeda pharmaceuticals america, inc. - vortioxetine hydrobromide (unii: tks641koay) (vortioxetine - unii:3o2k1s3wqv) - vortioxetine 5 mg - trintellix is indicated for the treatment of major depressive disorder (mdd) in adults. - hypersensitivity to vortioxetine or any component of the formulation. hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported in patients treated with trintellix [see adverse reactions (6.2)] . - the use of maois intended to treat psychiatric disorders with trintellix or within 21 days of stopping treatment with trintellix is contraindicated because of an increased risk of serotonin syndrome. the use of trintellix within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.4), warnings and precautions (5.2)] . starting trintellix in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see warnings and precautions (5.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monit